GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (NAS:ESPR) » Definitions » FCF Yield %

Esperion Therapeutics (Esperion Therapeutics) FCF Yield % : -6.28 (As of May. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Esperion Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Esperion Therapeutics's Trailing 12-Month Free Cash Flow is $-27.4 Mil, and Market Cap is $435.8 Mil. Therefore, Esperion Therapeutics's FCF Yield % for today is -6.28%.

The historical rank and industry rank for Esperion Therapeutics's FCF Yield % or its related term are showing as below:

ESPR' s FCF Yield % Range Over the Past 10 Years
Min: -210.08   Med: -37.75   Max: -0.93
Current: -6.28


During the past 13 years, the highest FCF Yield % of Esperion Therapeutics was -0.93%. The lowest was -210.08%. And the median was -37.75%.

ESPR's FCF Yield % is ranked worse than
70.15% of 1082 companies
in the Drug Manufacturers industry
Industry Median: -0.52 vs ESPR: -6.28

Esperion Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 39.03%.


Esperion Therapeutics FCF Yield % Historical Data

The historical data trend for Esperion Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics FCF Yield % Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.35 -14.62 -86.67 -37.63 -38.33

Esperion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -156.74 -70.61 -70.34 -41.94 42.71

Competitive Comparison of Esperion Therapeutics's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's FCF Yield % falls into.



Esperion Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Esperion Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-135.487 / 353.4479
=-38.33%

Esperion Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=53.755 * 4 / 503.4514
=42.71%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Esperion Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (Esperion Therapeutics) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Executives
Eric Warren officer: Chief Commercial Officer 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
J Martin Carroll director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Sheldon L. Koenig officer: Chief Operating Officer C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joanne M. Foody officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Benjamin Looker officer: General Counsel C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Benjamin Halladay officer: Chief Financial Officer ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Alan Fuhrman director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben director, officer: Pres & Chief Executive Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Tracy M Woody director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
Richard Bartram officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121